About The iCMLf Prizes
The iCMLf Prizes are among the most prestigious awards in the field of Chronic Myeloid Leukemia, recognising outstanding contributions to advancing CML research, clinical care, and global collaboration. Running since 2009, these awards highlight the exceptional work of clinicians, researchers, and patient advocates who have made significant strides in improving outcomes for CML patients worldwide.
Each prize is carefully designed to honor excellence in specific areas of CML care and research:
The Rowley Prize
The iCMLf Rowley Prize named after Dr Janet Rowley recognises individuals who have made exceptional lifetime achievements in advancing the understanding of the biology of CML. Prior to her death in 2013, Dr Rowley was the Blum-Riese Distinguished Service Professor of Medicine, Molecular Genetics and Cell Biology and Human Genetics at the University of Chicago. In 1973 she made a seminal discovery in CML when she used newly developed chromosome banding techniques to show that the Philadelphia chromosome is formed by a translocation between chromosomes 9 and 22. This discovery led to the eventual identification of the fusion gene BCR-ABL and ultimately to the development of targeted inhibitors of this leukemia-specific oncoprotein.
The Goldman Prize
The iCMLf Goldman Prize honors individuals who have demonstrated extraordinary dedication and achievements in the management and treatment of CML. This award has been created in memory of the late iCMLf chair, John Goldman, to honour his commitment to clinical excellence in treating CML. John Goldman was an outstanding scientist with a worldwide recognition and a leading figure in CML research. During his career of over 40 years he made seminal contributions to a variety of breakthroughs in CML research particularly in the field of stem cell transplantation, in the clinical development of new therapies and in the advancements of diagnostics. He was the first to demonstrate the presence of stem cells in the peripheral blood of CML patients and their potential role in autografting patients with CML.
The iCMLf Prize
The iCMLf Prize acknowledges outstanding achievements to low- and middle-income countries to address unequal access to monitoring and treatment of CML.
These awards are renowned not only for their global scope but also for the caliber of recipients, who represent the leading innovators and thought leaders in CML. Winning an iCMLf Prize is a testament to exceptional dedication, expertise, and influence in the field. By celebrating these achievements, the iCMLf aims to inspire continued progress in the fight against CML and to promote global collaboration in pursuit of a cure.